Earp L J, Delos S E, Park H E, White J M
Department of Microbiology, University of Virginia, Charlottesville, VA, USA.
Curr Top Microbiol Immunol. 2005;285:25-66. doi: 10.1007/3-540-26764-6_2.
Every enveloped virus fuses its membrane with a host cell membrane, thereby releasing its genome into the cytoplasm and initiating the viral replication cycle. In each case, one or a small set of viral surface transmembrane glycoproteins mediates fusion. Viral fusion proteins vary in their mode of activation and in structural class. These features combine to yield many different fusion mechanisms. Despite their differences, common principles for how fusion proteins function are emerging: In response to an activating trigger, the metastable fusion protein converts to an extended, in some cases rodlike structure, which inserts into the target membrane via its fusion peptide. A subsequent conformational change causes the fusion protein to fold back upon itself, thereby bringing its fusion peptide and its transmembrane domain-and their attached target and viral membranes-into intimate contact. Fusion ensues as the initial lipid stalk progresses through local hemifusion, and then opening and enlargement of a fusion pore. Here we review recent advances in our understanding of how fusion proteins are activated, how fusion proteins change conformation during fusion, and what is happening to the lipids during fusion. We also briefly discuss the therapeutic potential of fusion inhibitors in treating viral infections.
每种包膜病毒都会将其膜与宿主细胞膜融合,从而将其基因组释放到细胞质中并启动病毒复制周期。在每种情况下,一种或一小部分病毒表面跨膜糖蛋白介导融合。病毒融合蛋白的激活方式和结构类别各不相同。这些特征共同产生了许多不同的融合机制。尽管它们存在差异,但融合蛋白如何发挥作用的共同原则正在显现:响应激活触发因素,亚稳态融合蛋白转变为伸展的结构,在某些情况下为棒状结构,该结构通过其融合肽插入靶膜。随后的构象变化导致融合蛋白自身折叠,从而使其融合肽和跨膜结构域以及它们附着的靶膜和病毒膜紧密接触。随着初始脂质柄通过局部半融合,然后融合孔打开并扩大,融合随之发生。在这里,我们综述了我们对融合蛋白如何被激活、融合过程中融合蛋白如何改变构象以及融合过程中脂质发生了什么的最新认识进展。我们还简要讨论了融合抑制剂在治疗病毒感染方面的治疗潜力。